ANZAN 2024 Novartis Posters
Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results from Structured Interviews
Presenter: John Parratt
Prognostic Value of On-Treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People With Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials
Presenter: Jeanette Lechner-Scott
Longer-term Safety and Efficacy of Ofatumumab in People With Relapsing Multiple Sclerosis for Up to 6 years
Presenter: Suzanne Hodgkinson
Cumulative Pregnancy Outcomes in Patients With Multiple Sclerosis Following Maternal Exposure to Ofatumumab: Results From the Novartis Safety Database
Presenter: Naomi Burke
Characterizing the use of ofatumumab - a Secondary Use of Data Study characterizing ofatumumab utilisation in relapsing multiple sclerosis patients (EAFToS)
Presenter: Anneke Van Der Walt
Utilisation of High Efficacy Therapy for Managing Multiple Sclerosis in Australia
Presenter: Pamela McCombe
Real-world Australian experience with Ofatumumab in the MSBase Registry
Presenter: Margaret Migocki
The content of this page is provided for the purpose of medical education only, and may include information on unregistered products or off-label topics. Please review the Australian Product Information before prescribing, available at www.tga.gov.au. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.
Medical Information Service
Medical Enquires, Information services, Adverse Events and Product Complaints please contact:
Telephone: 1800 671 203
Mail: [email protected]
Colleagues are available from 9:00 to 17:00 from Monday to Friday
Please review Product Information before prescribing available at www.novartis.com/au-en/products/healthcare-professionals.
For medical enquiries please contact 1800 671 203.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/safety/reporting-problems.
For Ofatumumab prescribing information, please click here.
For Ofatumumab PBS status, please click here.
For Siponimod prescribing information, please click here.
For Siponimod PBS status, please click here.